STX.L实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (10 May 2024 @ 16:54):

Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of clinical stage pharmaceuticals to treat unmet medical needs...

Stats
今日成交量	1.04M
平均成交量	7.36M
市值	11.30M
EPS	£0 ( 2024-04-29 )
Last Dividend	£0 ( N/A )
Next Dividend	£0 ( N/A )
P/E	-0.120
ATR14	£0.0260 (1.80%)

Shield Therapeutics PLC 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Shield Therapeutics PLC 财务报表

Annual	2022
营收:	£4.47M
毛利润:	£2.00M (44.71 %)
EPS:	£-0.170

FY	2022
营收:	£4.47M
毛利润:	£2.00M (44.71 %)
EPS:	£-0.170

FY	2021
营收:	£1.52M
毛利润:	£539 000 (35.48 %)
EPS:	£-0.165

FY	2020
营收:	£10.39M
毛利润:	£9.03M (86.96 %)
EPS:	£-0.0200

Financial Reports:

No articles found.

Shield Therapeutics PLC

Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of clinical stage pharmaceuticals to treat unmet medical needs. The company's lead product is Accrufer/Feraccru, a non-salt based oral therapy for the treatment of iron deficiency with or without anemia in adults. It also develops PT20, a novel iron-based phosphate binder that has completed its Phase II pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company was founded in 2008 and is based in Gateshead, the United Kingdom.